Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis

Glucagon-like Peptide-1 receptor agonists (GLP1-ra) are a relatively new class of anti-hyperglycemic drugs which may positively affect bone metabolism and thereby decrease (osteoporotic) bone fracture risk. Data on the effect of GLP1-ra on fracture risk are scarce and limited to clinical trial data...

Descripción completa

Detalles Bibliográficos
Autores principales: Driessen, Johanna H. M., Henry, Ronald M. A., van Onzenoort, Hein A. W., Lalmohamed, Arief, Burden, Andrea M., Prieto-Alhambra, Daniel, Neef, Cees, Leufkens, Hubert G. M., de Vries, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491344/
https://www.ncbi.nlm.nih.gov/pubmed/25894068
http://dx.doi.org/10.1007/s00223-015-9993-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491344/
https://www.ncbi.nlm.nih.gov/pubmed/25894068
http://dx.doi.org/10.1007/s00223-015-9993-5

Ejemplares similares